270,100 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Acquired by J. Goldman & Co LP

J. Goldman & Co LP purchased a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 270,100 shares of the biotechnology company's stock, valued at approximately $413,000. J. Goldman & Co LP owned 0.18% of Heron Therapeutics at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in HRTX. Nicolet Advisory Services LLC bought a new position in shares of Heron Therapeutics in the fourth quarter valued at approximately $25,000. Argent Advisors Inc. bought a new position in shares of Heron Therapeutics in the fourth quarter valued at approximately $31,000. Focus Partners Wealth bought a new position in shares of Heron Therapeutics in the fourth quarter valued at approximately $31,000. Cutter & CO Brokerage Inc. boosted its holdings in shares of Heron Therapeutics by 69.6% in the fourth quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock valued at $51,000 after acquiring an additional 13,600 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Heron Therapeutics by 23.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,179 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 8,684 shares in the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Stock Up 5.3%

NASDAQ:HRTX traded up $0.10 during trading hours on Friday, reaching $1.97. 1,254,610 shares of the company's stock were exchanged, compared to its average volume of 2,320,510. The company has a market capitalization of $300.55 million, a P/E ratio of -10.94 and a beta of 1.33. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The business's 50-day simple moving average is $2.14 and its two-hundred day simple moving average is $1.82.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million for the quarter, compared to the consensus estimate of $37.08 million. As a group, sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, April 11th. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, March 8th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.